IBI-3026

N/A

Report date: 2026/02/11 20:01:36
First In Class

Base Information

Drug NameIBI-3026
Drug Alias NameIBI3026IBI-3026
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 agonistsInterleukin-12 agonists
TargetsProgrammed cell death protein 1Interleukin-12
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovent Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics Technology Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A